Advertisement

Topics

Companies Related to "Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection" [Most Relevant Company Matches] RSS

19:45 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection" found in our extensive corporate database of over 50,000 company records.

Showing "Phase Study High Dose Acyclovir Central Nervous System" Companies 1–25 of 8,400+

Extremely Relevant

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...


Lundbeck

Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D efforts to central nervous system (CNS) disorders.

Cypress Bioscience

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications....


Relevant

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Euthymics Bioscience, Inc.

DOV is a biopharmaceutical company historically focused on the development of novel product candidates for disorders of the central nervous system. DOV has previously funded drug development and discovery programs that are now at the preclinical, Phase I and Phase II clinical stages focused on monoamine reuptake inhibitors.

ACADIA Pharmaceuticals Inc.

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is currently developing a portfolio consisting of four product candidates including pimavanserin, which is being developed for three separate neurological and psychiatric indi...

Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of pri...

DOV Pharmaceutical

We are a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system, cardiovascular and urological disorders. We have five product candidates in clinical trials addressing therapeutic indications with significant unmet needs. Our product candidate for insomnia is currently in Phase III clinical trials and o...

Neurologix

Neurologix, Inc., a leader in the development of innovative therapies for the brain and central nervous system, utilizes gene therapy and other novel technologies. The central nervous system ("CNS") is a new and particularly exciting target for gene therapy because its unique properties prevent the successful treatment of many neurological disorders by conventional means such as drug therapy and s...

AGY Therapeutics

AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system. AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specifi...

Elbion AG

elbion discovers and develops new small molecule drugs. Inflammatory and central nervous system diseases with high unmet medical need and high commercial potential are at the center of elbion's project pipeline, which covers all stages from early "hits" to advanced clinical projects.

Karuna Pharmaceuticals, Inc.

Karuna is a clinical-stage drug development company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders, including schizophrenia and Alzheimer’s disease, as well as pain. Karuna’s lead product candidate, KarXT (Karuna-Xanomeline-Trospium), is being evalua...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

TorreyPines Therapeutics

We are a clinical stage biopharmaceutical company committed to discovering, developing and commercializing novel small molecules to treat diseases and disorders of the central nervous system (CNS). Our initial focus is on delivering potentially next generation therapies for chronic pain, including migraine, and cognitive disorders such as cognitive impairment associated with schizophrenia (CIAS) a...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Group Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, a biotechnology company that is the world leader in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a b...

Medpace Holdings, Inc.

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, hig...

Phase 2 Discovery, Inc.

Phase 2 Discovery (P2D) is a pharmaceutical company focused on developing innovative drugs that fulfill unmet medical needs in the treatment of central nervous system (CNS) disorders such as insomnia, anxiety, depression, attention disorders and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).At P2D, we are using our understanding of the treatme...

SkeleTech, Inc.

SkeleTech is a therapeutically focused contract research organization providing pre-clinical discovery and development services in Bone and Central Nervous System (CNS) biologies.The Company's wide range of capabilities reflects years of experience in the study of human bone and CNS disorders. This experience enables SkeleTech to offer a wide range of scientific and technical expertise in model d...

Neuro3d

Neuro3d is a young pharmaceutical company aiming at development of new innovative treatments for central nervous system disorders. Neuro3d is a partially virtual company capable of discovering new active compounds and develop them quickly through Phase IIa. Neuro3d's present research focus is on depression, anxiety and schizophrenia. Neuro3d has produced innovative treatment concepts and managed t...

Axonia Medical

Axonia Medical is a privately owned-company located in Kalamazoo MI, founded by the University of Pennsylvania, Dr. Douglas H. Smith, The Robert A. Groff Endowed Professor and Vice Chairman for Research, Department of Neurosurgery, University of Pennsylvania, and Dr. Harry C. Ledebur, Fmr. Executive in Residence at Southwest Michigan Life Science Venture F...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

BioAxone BioSciences, Inc.

BioAxone BioSciences is a clinical-stage biotechnology company developing innovative drugs to restore neurological function for patients with Spinal Cord Injuries (SCI) and other malformations in central nervous system with unmet medical needs. Led by a team of scientists renowned for their work on axon regeneration and neuronal signaling pathways, BioAxon...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...


More From BioPortfolio on "Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks